一项前瞻性多中心试验:比较PSMA-PET与FDG-PET对新诊断高危前列腺癌的分期价值
这项前瞻性多中心试验于2021年10月至2023年1月在三家中心招募32例高危前列腺癌患者,均接受PSMA PET-CT分期并集中行FDG PET-CT。结果显示FDG-PET未检出任何额外明确或可能转移,未改变任何患者的管理,结论认为FDG-PET在PSMA-PET之上未提供额外分期信息。
要点
- FDG-PET未检出任何额外明确或可能转移,未改变任何患者的管理。
- 所有肿瘤均显示PSMA摄取,5例患者经PSMA-PET观察到更高分期。
- 34%的患者原发肿瘤无FDG摄取。
核心结论
- FDG-PET在新诊断高危前列腺癌患者中未在PSMA-PET之上提供额外分期信息,也未改变管理。
研究设计与样本
- 前瞻性多中心试验,于2021年10月至2023年1月在三家中心招募32例新诊断高危(EAU分类)前列腺癌患者,均接受PSMA PET-CT分期,FDG PET-CT集中采集并使用标准化模板报告。
主要发现
- 中位年龄69岁,中位PSA为14 ug/L,大多数患者PI-RADS评分为5分(59%)且ISUP分级分组为5组(66%)。
- 总体上,按医师判读,FDG-PET未检出任何额外明确或可能转移。
- 所有肿瘤均显示PSMA摄取,5例患者经PSMA-PET观察到更高分期。
- 34%的患者原发肿瘤无FDG摄取。
- FDG-PET未导致任何患者的管理改变。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite being a potentially attractive alternative molecular imaging modality due to wider availability and association with lethal disease in advanced prostate cancer, the role of fluorodeoxyglucose (FDG)- positron emission tomography (PET) at initial diagnosis compared to Prostate Specific Membrane Antigen (PSMA) PET is yet to be accurately determined. The aim of this study was to evaluate the additive benefit of FDG PET to PSMA PET in patients with newly diagnosed, high risk prostate cancer. RESULTS: A prospective trial conducted across three sites between October-2021 and January-2023 recruited 32 participants with high risk (EAU classification) prostate cancer staged with PSMA PET-CT. FDG PET-CT was acquired centrally and reported with a standardised template. Median age was 69 years, median PSA was 14 ug/L, and most had PI-RADS 5 scores (59%) and ISUP Grade Group 5 tumours (66%). Overall, FDG-PET did not detect any additional definite/probable metastasis according to physician interpretation. All tumours showed PSMA avidity and higher stage was observed per PSMA-PET in 5 participants. No FDG uptake at the primary tumour occurred in 34% of participants. FDG-PET did not result in a change in management for any participant. PSA remission rates were lower in patients with stage ≥ 3 tumours on MRI (60% vs 94%, p = 0.04). Patient reported outcomes (PROs) were largely stable throughout the study. CONCLUSIONS: FDG-PET did not provide additive staging information above PSMA-PET or alter management for newly diagnosed high-risk prostate cancer patients. TRIAL REGISTRATION NUMBER: ANZCTR ACTRN12621001185853. Registered 03-09-2021. Available at https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=382299.
引用
- Roberts MJ, Roberts NA, Pelecanos A, et al. A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer. EJNMMI Res. 2025. PMID: 40705116. doi:10.1186/s13550-025-01265-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。